Dihydroergotamine-Erythromycin-Induced Ergotism
Authors: Fabrice Leroy
Journal: Annals of Internal Medicine (1988)

Letters and Corrections1 August 1988Dihydroergotamine-Erythromycin-Induced ErgotismFabrice Leroy, MD, Philippe Asseman, MD, Philippe Pruvost, MD, Pascal Adnet, MD, Dominique Lacroix, MD, Claude Thery, MDFabrice Leroy, MDSearch for more papers by this author, Philippe Asseman, MDSearch for more papers by this author, Philippe Pruvost, MDSearch for more papers by this author, Pascal Adnet, MDSearch for more papers by this author, Dominique Lacroix, MDSearch for more papers by this author, Claude Thery, MDSearch for more papers by this authorAuthor, Article, and Disclosure Informationhttps://doi.org/10.7326/0003-4819-109-3-249_1 SectionsAboutPDF ToolsAdd to favoritesDownload CitationsTrack CitationsPermissions ShareFacebookTwitterLinkedInRedditEmail ExcerptTo the editor: Acute ergotism is a iatrogenic disease usually seen in young patients being treated with ergotamine tartrate. Concurrent treatment with troleandomycin, a macrolide antibiotic, for an intercurrent febrile illness can be a precipitative factor. We report an unusual case of ergotism.A 71-year-old man was hospitalized for acute ischemia of the upper limbs. The patient had a long history of migraines, which were treated with dihydroergotamine (30 drops, three times daily). He had been taking erythromycin for a pulmonary infection, (2 g daily) 3 days before admission. At admission, both arms were ice-cold and were painful at rest....References1. Catterer R. Ergotism as a complication of thrombo-embolic prophylaxis with heparin and dihydroergotamine. Lancet. 1986;2:638-9. CrossrefGoogle Scholar2. BoucharlatFrancoCarpentierCharignonDenisHommel JAPYBM. Ergotisme en milieu psychiatrique par association D.H.E.-proprionate d'érythromycine: à propos d'une observation. Ann Med Psychol. 1980;138:292-6. MedlineGoogle Scholar3. NeveuxLesgourguesLutonGuilhaumeBertagnaPicard EBJBJ. Ergotisme aigu par association proprionate d'érythromycine-dihydroergotamine. Nouv Presse Med. 1981;10:2830. MedlineGoogle Scholar This content is PDF only. To continue reading please click on the PDF icon. Author, Article, and Disclosure InformationAuthors: Fabrice Leroy, MD; Philippe Asseman, MD; Philippe Pruvost, MD; Pascal Adnet, MD; Dominique Lacroix, MD; Claude Thery, MDAffiliations: Hôpital Cardiologie 59037 Lille Cedex France PreviousarticleNextarticle Advertisement FiguresReferencesRelatedDetails Metrics Cited byInhaled drug therapy development for the treatment of migraineDihydroergotamine, Ergotamine, Methysergide and Sumatriptan - Basic Science in Relation to Migraine TreatmentLack of drug interaction between the migraine drug MAP0004 (orally inhaled dihydroergotamine) and a CYP3A4 inhibitor in humansPrevalence and predictors of potential drug–drug interactions in Regione Emilia-Romagna, ItalyPharmacokinetics and interactions of headache medications, part I: introduction, pharmacokinetics, metabolism and acute treatmentsPharmacokinetics and interactions of headache medications, part II: prophylactic treatmentsPharmacokinetic Aspects of Treating Infections in the Intensive Care UnitClinically Significant Drug Interactions with Agents Specific For Migraine AttacksErgotamine/caffeine treatment of orthostatic hypotension in parkinsonism with autonomic failureDouble-Blind, Multicenter Trial to Compare the Efficacy of Intramuscular Dihydroergotamine Plus Hydroxyzine Versus Intramuscular Meperidine Plus Hydroxyzine for the Emergency Department Treatment of Acute Migraine HeadacheAcute Upper Extremity Ischemia during Concomitant Use of Ergotamine Tartrate and AmpicillinErythromycin-Associated Ergotamine Intoxication: Arteriographic and Electrophysiologic Analysis of a Rare Cause of Severe Ischemia of the Lower Extremities and Associated Ischemic Neuropathy 1 August 1988Volume 109, Issue 3Page: 249-249KeywordsAntibioticsErythromycinIschemiaMigrainePulmonary diseases ePublished: 1 December 2008 Issue Published: 1 August 1988 PDF downloadLoading ...